The firm is investigating the all-stock merger between Werewolf Therapeutics (HOWL) and Ambros Therapeutics, a deal focused on the advancement of a CRPS-1 treatment program. Concurrently, the firm is reviewing the $1.5 billion acquisition of MarineMax (HZO) by Francisco Partners, which involves a cash payout of $53.00 per share and specific change-of-control benefits for company insiders.

Legal scrutiny also extends to the proposed sale of Tri-County Financial Group (TYFG) to HBT Financial. Shareholders in this transaction are presented with a choice between HBT common stock, a cash payment of $71.01 per share, or a blend of both, resulting in an implied purchase price of $82.89. Finally, the firm is looking into the merger involving Fulcrum Therapeutics (FULC) and Francisco Partners, where post-merger ownership stakes are subject to adjustment based on net cash levels at the closing date. Shareholders concerned about these deals are encouraged to contact the firm for further information.